Summary Loss of heterozygosity (LOH) on chromosome arm 16q occurs in 48-65% of breast tumours. One small region of overlap is located at 1 6q24.3. Two genes located in this region, the cellular adhesion regulatory molecule (CMAR) and the breast basic conserved gene (BBC1), are plausible candidate tumour-suppressor genes. Mutational analysis of the retained copy of these genes has been performed by direct sequencing in a selected set of breast tumours that show LOH at 1 6q24.3 but not at other regions on chromosome arm 1 6q. In CMAR no other alterations than the previously described 4-bp insertion of CACA at nucleotide 241 could be detected, which was also present in constitutional DNA of the same patients. This polymorphism occurs homozygously in germline DNA of normal individuals and breast cancer patients. LOH analysis at this locus shows no preferential loss of a particular variant of the 241 polymorphism. In the BBC1 gene, three different alterations were found, but only one resulted in an amino acid substitution. This is a known polymorphism, however, also appearing in germline DNA. The absence of tumour-specific mutations in CMAR and BBC1 in this selected series of breast tumours implies that another gene at 1 6q24.3 must be the tumour-suppressor gene that is the target for LOH in breast cancer.
Loss of heterozygosity (LOH) on the long arm of chromosome 16 occurs frequently in breast cancer and other tumours. Percentages of LOH in breast cancer vary from 48% to 65% in different regions of 16q in different studies (Cleton-Jansen et al, 1994; Tsuda et al, 1994; Dorion-Bonnet et al, 1995) . This suggests the presence of tumour-suppressor genes on this chromosome arm. One of two identified small regions of overlap is located at 16q24.3 between the markers APRT and D16S303 (Cleton-Jansen et al, 1994) .
Two genes, the cellular adhesion regulatory molecule (CMAR) and the breast basic conserved gene (BBCJ), located in this region are probable candidates for the gene targeted by LOH (Adams et al, 1992; Pullman and Bodmer, 1992; Cleton-Jansen et al, 1995a) . The CMAR gene product enhances binding of integrins to extracellular matrix components (Pullman and Bodmer, 1992) . A 4-bp insertion of CACA at nucleotide 241 occurs in 38% of Caucasians and in 30% of Japanese (Koyama et al, 1992; Durbin et al, 1994) . This 4-bp insertion probably results in an alternative start site for the gene (Durbin et al, 1994) .
The BBC] gene was identified by differential screening of cDNA libraries of a primary breast carcinoma and of a benign fibroadenoma (Adams et al, 1992) . Expression of this gene is higher in fibroadenomas than in carcinomas. The gene is expressed in a great variety of tissues and it is also highly conserved in other species (Bertauche et al, 1994) . At the genetic level 85% homology is found with the gene coding for the rat ribosomal protein L13, at the protein level 97% homology is found (Olvera et al, 1994 (Figure 1 ). This set was selected from a series of 230 sporadic breast tumours on which LOH analysis had been performed with 37 polymorphic markers on chromosome arm 16q (partly described in Cleton-Jansen et al, 1994) .
For estimating the allele frequencies of the polymorphisms described here, control DNA isolated from healthy unrelated individuals from the Leiden region was used. Mutation analysis of CMAR Non-32P-labelled CMAR PCR fragments were screened for mutations after Easy Prep system purification (Pharmacia) by cycle sequencing (1 min at 95°C; 1 min at 55°C; and 1.5 min at 720C for 32 cycles) with a cycle-sequencing kit (Amplicycle sequencing kit, Perkin Elmer) with nested primers:
Screening of the BBC1 gene RNA was isolated from frozen breast tumour tissue using TRIZOL reagent (Gibco BRL). Reverse transcription was performed on 2 ig of total RNA, using an Oligo(dT) primer and 5 U of AMV reverse transcriptase (Boehringer Mannheim), in 20-,ul reactions containing the recommended buffer, 5 U of RNAsin (Promega) and 1 mM dNTPs. PCR reactions were performed on 1 p1 of cDNA (1 min at 95°C; 1 min at 59°C; and 1.5 min at 720C for 32 cycles).
Primers used for amplification of the BBC] coding sequence:
BBC For: 5'-TlTCCGCTCGGCTGTTTT-3' BBC Rev: 5'-CGACTGATTCCAAGTCCCC-3' Cycle sequencing (1 min at 95°C; 1 min at 60°C; and 1.5 min at 72°C for 32 cycles) was performed using the following primers: BBC For nest: 5'-GCAGGAGCCGCAGGGCCGTAG-3' BBC Rev nest: 5'-GTCCCCAGGAGGGCTTrATT-3' BBC 10-9 (For): 5'-GGTACCACACGAAGGTGCGC-3' (kindly provided by S Adams).
Detection of the BBC1 polymorphism on genomic DNA A first non-radioactive PCR was performed on 100 ng of DNA in a 50-,ul volume (1 min at 95°C; 1 min at 55°C; and 1.5 min at 72°C for 12 cycles).
BBC 10-10 (For): 5'-CTCTGTTGGCCTCAGTCGCG-3' BBC 620 (Rev): 5'-ACTCCTTCAGCCGCTG-3' (both primers provided by S Adams). A second, seminested PCR was carried out at the same conditions, for 20 cycles with 1-gl input from the first PCR and incorporation of 32P, in a reaction volume of 50,l. (Table 1 ). The occurrence of this polymorphism is similar to previously described frequencies of 30% (Koyama et al, 1992) and 38% (Durbin et al, 1994) . However, homozygosity of 241 A InsCACA has not been observed previously, probably because of low sample numbers. Figure 2A shows examples of homozygous allele 241 A, homozygous 241 A InsCACA and heterozygous CMAR alleles as detected by PCR and autoradiography.
The detection of two normal individuals that are homozygous for the CMAR 241 A InsCACA allele shows that absence of one of the variants of the CMAR polymorphism is not deleterious. This either implicates that the 241 A InsCACA allele encodes a functional protein or that CMAR is not an indispensable gene.
LOH at CMAR in breast tumours
Constitutional DNA of 172 breast cancer patients was used to determine the allele frequency of the CMAR 241 A InsCACA polymorphism. On 344 chromosomes, the frequency was 83% for allele 241 A and 17% for the 241 A InsCACA allele. Observed homo-and heterozygosity rates are similar to the frequencies observed in the normal control population as shown in Table 1. A series of 168 breast tumours was tested for LOH at the CMAR locus using the 241 A InsCACA polymorphism. Of the 38 informative cases 25 (66%) showed LOH. This high LOH rate is in concordance with previous results with other markers from this chromosomal region (Cleton-Jansen et al, 1994) . If CMAR is involved in tumour suppression, and if one of the variants encodes a less active protein, one would expect preferential loss of one of the alleles. However, of these cases 13 showed LOH of the 241 A allele and 12 showed LOH of the 241 A InsCACA, indicating no preferential loss of allele 241 A. Figure 2B shows examples of LOH of the 241 A (T3, T4) and the 241 A InsCACA (Ti) CMAR alleles.
British Journal of Cancer (1997) 76(12) Mutation analysis of CMAR in breast tumours Somatic mutation analysis for CMAR in breast cancer has been reported previously by Koyama et al (1992) , who did not detect mutations. However, Koyama et al did not screen the complete coding sequence, 21 nucleotides are missing because one of the primers used is located in the coding sequence. As not all breast tumours show LOH at 16q and as this chromosome arm is suspected to contain at least two different tumour-suppressor genes, we have repeated this analysis on a more specific set of breast cancer cases, i.e. tumours with LOH only at 16q24.3, not on other regions of chromosome arm 16q (Figure 1 ). Figure 1 shows the LOH results obtained with markers on 16q24.3 and more proximal markers, which were described in Cleton-Jansen et al (1994) . The CMAR gene does not have introns and the complete sequence was amplified in one PCR reaction on genomic DNA from the tumours, using primers according to the submitted sequence (GenBank accession no. S54769) and the sequence from 3'UTR that was determined by sequencing a CMAR-positive cosmid, NL-87D4. Subsequent sequencing of these PCR products revealed no sequence deviations other than the already known polymorphism (Figure 1 ).
Mutation analysis of BBC1 in breast tumours and polymorphisms in the BBC1 gene the complete coding sequence of BBC] were generated from this tumour cDNA and sequenced. Three different deviations from the GenBank sequence were found in this gene (Figure 1) , two of which did not result in an amino acid change, 144 T -> G and 192 C -* T. One alteration, 385 A -* G resulted in an amino acid substitution, but this is a known polymorphism (J Varley, personal communication) that appears also in germline DNA from the same patient. Table 1 shows the frequency of the polymorphisms found in this study.
Polymorphism 385 G, the only alteration that results in an amino acid change, occurs in 11 tumours whereas the 385 A allele, concordant with the GenBank sequence, is seen in only two cases. To determine whether this is a preferential loss of the 385 A allele, we examined constitutional DNA extracted from peripheral lymphocytes from the same patients. A two-step PCR was designed: the first PCR with a forward primer in intron 1 and the reverse primer in exon 2 to avoid amplification of pseudo genes British Journal of Cancer (1997) 76 (12) (Adams et al, 1992) . As this PCR fragment contains numerous HaeIII sites a second nested PCR was performed, followed by a HaeIII digestion. From 11 tested DNAs, seven are homozygous for the 385 G allele. Two out of four heterozygous cases showed LOH of the 385 A allele and two cases showed LOH of the polymorphic 385 G allele. Apparently, there is no preferential loss of the 385 A allele.
Furthermore, we estimated the allele frequencies of polymorphism 385 in 30 healthy, unrelated individuals. In this series, one homozygous variant 385 A, 21 homozygous variant G and eight heterozygous individuals were found. In a total of 60 alleles this results in 10 (17%) variant A and 50 (83%) variant G alleles. This is in agreement with the allele frequency found in 13 breast cancer patients (Table 2) .
To assess that LOH has occurred at the BBCJ locus, allele intensities of normal and tumour DNA were determined by phosphoimager analysis. Imbalance factors (IF) were calculated as described previously (Cleton-Jansen et al, 1995b) . Because of the presence of heteroduplexes formed between wild-type and polymorphic strands that cannot be digested by HaeHI, these IFs are not representative of the LOH in these tumours.
Alterations other than the polymorphisms that are described here (Figure 1) could not be detected.
In conclusion, we have analysed two genes BBCI and CMAR on 16q24.3 that have been frequently suggested previously as candidate tumour-suppressor genes, in a selected population of breast tumours, showing only LOH at 16q24.3, not elsewhere on 16q. Neither mutations nor preferential loss of particular alleles have been detected. Therefore, it can be concluded that neither CMAR nor BBC1 but another gene at 16q24.3 is the target tumoursuppressor gene for LOH in breast cancer.
